<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39034937</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-0364</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American journal of medicine open</Title><ISOAbbreviation>Am J Med Open</ISOAbbreviation></Journal><ArticleTitle>Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review.</ArticleTitle><Pagination><StartPage>100068</StartPage><MedlinePgn>100068</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100068</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajmo.2024.100068</ELocationID><Abstract><AbstractText>The virus called SARS-CoV-2 emerged in 2019 and quickly spread worldwide, causing COVID-19. It has greatly impacted on everyday life, healthcare systems, and the global economy. In order to save as many lives as possible, precautions such as social distancing, quarantine, and testing policies were implemented, and effective vaccines were developed. A growing amount of data collected worldwide allowed the characterization of this new disease, which turned out to be more complex than other common respiratory tract infections. An increasing number of convalescents presented with a variety of nonspecific symptoms emerging after the acute infection. This possible new global health problem was identified and labelled as long COVID. Since then, a great effort has been made by clinicians and the scientific community to understand the underlying mechanisms and to develop preventive measures and effective treatment. The role of autoimmunity induced by SARS-CoV-2 infection in the development of long COVID is discussed in this review. We aim to deliver a description of several conditions with an autoimmune background observed in COVID-19 convalescents, including Guillain-Barr&#xe9; syndrome, antiphospholipid syndrome and related thrombosis, and Kawasaki disease highlighting a relationship between SARS-CoV-2 infection and the development of autoimmunity. However, further studies are required to determine its true clinical significance.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koz&#x142;owski</LastName><ForeName>Pawe&#x142;</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Central Laboratory, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leszczy&#x144;ska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Central Laboratory, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciepiela</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Central Laboratory, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Open</MedlineTA><NlmUniqueID>9918316788906676</NlmUniqueID><ISSNLinking>2667-0364</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Guillain-Barr&#xe9; syndrome</Keyword><Keyword MajorTopicYN="N">Kawasaki disease</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39034937</ArticleId><ArticleId IdType="pmc">PMC11256271</ArticleId><ArticleId IdType="doi">10.1016/j.ajmo.2024.100068</ArticleId><ArticleId IdType="pii">S2667-0364(24)00005-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Platto S., Wang Y., Zhou J., Carafoli E. History of the COVID-19 pandemic: origin, explosion, worldwide spreading. Biochem Biophys Res Commun. 2021;538:14&#x2013;23. doi: 10.1016/j.bbrc.2020.10.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.087</ArticleId><ArticleId IdType="pmc">PMC7834510</ArticleId><ArticleId IdType="pubmed">33199023</ArticleId></ArticleIdList></Reference><Reference><Citation>Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/Emergencies/Diseases/Novel-Coronavirus-2019/Technical-Guidance/Naming-the-Coronavirus-Disease-(Covid-2019)-and-the-Virus-That-Causes-It. Retreived Aug 18, 2023.</Citation></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio-Medica Atenei Parm. 2020;91(1):157&#x2013;160. doi: 10.23750/abm.v91i1.9397.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . World Health Organization; Geneva: 2023. World Health Statistics 2023: Monitoring Health For the SDGs, Sustainable Development Goals. Licence: CC BY&#x2011;NC&#x2011;SA 3.0 IGO.</Citation></Reference><Reference><Citation>Gupta A., Madhavan Mahesh V., Madhavan M.V., et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017&#x2013;1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831&#x2013;840. doi: 10.1001/jamacardio.2020.1286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1286</ArticleId><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020;14(3):247&#x2013;250. doi: 10.1016/j.dsx.2020.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.03.013</ArticleId><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilazi M., Duffy E.Y., Thakkar A., Michos E.D. COVID and cardiovascular disease: what we know in 2021. Curr Atheroscler Rep. 2021;23(7):37. doi: 10.1007/s11883-021-00935-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-021-00935-2</ArticleId><ArticleId IdType="pmc">PMC8117457</ArticleId><ArticleId IdType="pubmed">33983522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor S.K., Laukkanen J.A. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020;52(7):345&#x2013;353. doi: 10.1080/07853890.2020.1790643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1790643</ArticleId><ArticleId IdType="pmc">PMC7877945</ArticleId><ArticleId IdType="pubmed">32643418</ArticleId></ArticleIdList></Reference><Reference><Citation>Naicker S., Yang C.W., Hwang S.J., et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824&#x2013;828. doi: 10.1016/j.kint.2020.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7133222</ArticleId><ArticleId IdType="pubmed">32204907</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B., Wang C., Feng Z., et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nature communications. 2021;12(1):2506. doi: 10.1101/2020.03.04.20031120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.04.20031120</ArticleId><ArticleId IdType="pmc">PMC8096808</ArticleId><ArticleId IdType="pubmed">33947851</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Wu M., Yao J., et al. Caution on kidney dysfunctions of COVID-19 patients. medRxiv. 2020:1&#x2013;11. doi: 10.2139/ssrn.3559601.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3559601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao R., Qiu Y., He J.S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667&#x2013;678. doi: 10.1016/S2468-1253(20)30126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30126-6</ArticleId><ArticleId IdType="pmc">PMC7217643</ArticleId><ArticleId IdType="pubmed">32405603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Jiang X., Zhang Z., et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997&#x2013;1001. doi: 10.1136/gutjnl-2020-321013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321013</ArticleId><ArticleId IdType="pubmed">32241899</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F., Tang M., Zheng X., et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831. doi: 10.1053/j.gastro.2020.02.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.02.055</ArticleId><ArticleId IdType="pmc">PMC7130181</ArticleId><ArticleId IdType="pubmed">32142773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal&#x2013;oral transmission. Gastroenterology. 2020;158(6):1518&#x2013;1519. doi: 10.1053/j.gastro.2020.02.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.02.054</ArticleId><ArticleId IdType="pmc">PMC7130192</ArticleId><ArticleId IdType="pubmed">32142785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatti A.U.R., Zreik J., Yolcu Y.U., et al. Nervous system involvement in SARS-coronavirus infection: a review on lessons learned from the previous outbreaks, ongoing pandemic and what to expect in the future. Int J Neurosci. 2022;132(9):930&#x2013;938. doi: 10.1080/00207454.2020.1853724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2020.1853724</ArticleId><ArticleId IdType="pubmed">33208006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Jagadeesh H., Saxena A., et al. Central nervous system as a target of novel coronavirus infections: potential routes of entry and pathogenic mechanisms. J Biosci. 2021;46(4):106. doi: 10.1007/s12038-021-00232-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12038-021-00232-9</ArticleId><ArticleId IdType="pmc">PMC8612883</ArticleId><ArticleId IdType="pubmed">34840148</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha N.K., Ojha S., Jha S.K., et al. Evidence of coronavirus (CoV) pathogenesis and emerging pathogen SARS-CoV-2 in the nervous system: a review on neurological impairments and manifestations. J Mol Neurosci. 2021;71(11):2192&#x2013;2209. doi: 10.1007/s12031-020-01767-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01767-6</ArticleId><ArticleId IdType="pmc">PMC7814864</ArticleId><ArticleId IdType="pubmed">33464535</ArticleId></ArticleIdList></Reference><Reference><Citation>Andalib S., Biller J., Napoli M.D., et al. Peripheral nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep. 2021;21:1&#x2013;14. doi: 10.1007/s11910-021-01102-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-021-01102-5</ArticleId><ArticleId IdType="pmc">PMC7882462</ArticleId><ArticleId IdType="pubmed">33586020</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzano A.V., Cassano N., Genovese G., et al. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol. 2020;183(3):431&#x2013;442. doi: 10.1111/bjd.19264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19264</ArticleId><ArticleId IdType="pmc">PMC7300648</ArticleId><ArticleId IdType="pubmed">32479680</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J.L., Kamceva M., Rao S.A., et al. Cutaneous manifestations of COVID-19: a preliminary review. J Am Acad Dermatol. 2020;83(2):687&#x2013;690. doi: 10.1016/j.jaad.2020.05.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.05.059</ArticleId><ArticleId IdType="pmc">PMC7229462</ArticleId><ArticleId IdType="pubmed">32422225</ArticleId></ArticleIdList></Reference><Reference><Citation>Larenas-Linnemann D., Luna-Pech J.A., Navarrete-Rodr&#xed;guez E.M., et al. Cutaneous manifestations related to COVID 19 immune dysregulation in the pediatric age group. Curr Allergy Asthma Rep. 2021;21(2):13. doi: 10.1007/s11882-020-00986-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11882-020-00986-6</ArticleId><ArticleId IdType="pmc">PMC7905763</ArticleId><ArticleId IdType="pubmed">33630167</ArticleId></ArticleIdList></Reference><Reference><Citation>What happens to people who get COVID-19? https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19. Retreived Aug 18, 2023.</Citation></Reference><Reference><Citation>Alshrari A.S., Hudu S.A., Mohd Imran, et al. Innovations and development of Covid-19 vaccines: a patent review. J Infect Public Health. 2022;15(1):123&#x2013;131. doi: 10.1016/j.jiph.2021.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.10.021</ArticleId><ArticleId IdType="pmc">PMC8539827</ArticleId><ArticleId IdType="pubmed">34742639</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., Caricchio R., Casanova J.L., et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24) doi: 10.1172/jci154886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci154886</ArticleId><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanpanah N., Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2022;94(1):54&#x2013;62. doi: 10.1002/jmv.27292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27292</ArticleId><ArticleId IdType="pmc">PMC8661629</ArticleId><ArticleId IdType="pubmed">34427929</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., Buxton M., et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., et al. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021:372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P., Arora U., Kumar A., et al. The &#x201c;post-COVID&#x201d; syndrome: how deep is the damage? 2020;93(2):673&#x2013;674. 10.1002/jmv.26465</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26465</ArticleId><ArticleId IdType="pmc">PMC7461449</ArticleId><ArticleId IdType="pubmed">32852801</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen J.J.A., van de Vijver D.A.M.C., Fraaij P.L.A., et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat Commun. 2021;12(1):267. doi: 10.1038/s41467-020-20568-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20568-4</ArticleId><ArticleId IdType="pmc">PMC7801729</ArticleId><ArticleId IdType="pubmed">33431879</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V., Flanders S.A., O'Malley M., et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2020;174(4):576&#x2013;578. doi: 10.7326/m20-5661.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2020;27(2):258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M., Braillard O., Alcoba G., et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2020;174(5):723&#x2013;725. doi: 10.7326/m20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L., Baca S., Saydah S., et al. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, March 2020&#x2013;November 2021. Morb Mortal Wkly Rep. 2022;71(21):713&#x2013;717. doi: 10.15585/mmwr.mm7121e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId><ArticleId IdType="pmc">PMC9368731</ArticleId><ArticleId IdType="pubmed">35925799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M.L., King S., et al. Risk of long COVID in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. medRxiv. 2022 doi: 10.1101/2022.02.23.22271388. preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.23.22271388</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R., Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases. 2020;8(17):3621&#x2013;3644. doi: 10.12998/wjcc.v8.i17.3621.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v8.i17.3621</ArticleId><ArticleId IdType="pmc">PMC7479552</ArticleId><ArticleId IdType="pubmed">32953841</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. 2021;4(10):e2128568. doi:10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramirez D.C., Normand K., Zhaoyun Y., et al. Long-term impact of COVID-19: a systematic review of the literature and meta-analysis. Biomedicines. 2021;9(8):900. doi: 10.3390/biomedicines9080900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080900</ArticleId><ArticleId IdType="pmc">PMC8389585</ArticleId><ArticleId IdType="pubmed">34440104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. 2021;11(1):16144&#x2013;16144. 10.21203/rs.3.rs-266574/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-266574/v1</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M., Maralakunte M., Garg S., et al. The conundrum of &#x201c;Long-COVID-19&#x201d;: a narrative review. Int J Gen Med. 2021;14:2491&#x2013;2506. doi: 10.2147/ijgm.s316708.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ijgm.s316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Hartman T.C.O., Lucassen P., et al. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2013;167. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B.J., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S.L., Flanagan K.L. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626&#x2013;638. doi: 10.1038/nri.2016.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E., Malorni W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for a tailored therapy. Eur Respir J. 2022;52(2) doi: 10.1183/13993003.02245-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Koc H.C., Xiao J., Liu W., et al. Long COVID and its management. Int J Biol Sci. 2022;18(12):4768&#x2013;4780. doi: 10.7150/ijbs.75056.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.75056</ArticleId><ArticleId IdType="pmc">PMC9305273</ArticleId><ArticleId IdType="pubmed">35874958</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr Clin Res Rev. 2021;15(3):869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC9637465</ArticleId><ArticleId IdType="pubmed">36351871</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Vimercati L., De Maria L., Quarato M., et al. Association between long COVID and overweight/obesity. J Clin Med. 2021;10(18):4143. doi: 10.3390/jcm10184143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184143</ArticleId><ArticleId IdType="pmc">PMC8469321</ArticleId><ArticleId IdType="pubmed">34575251</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminian A., Bena J., Pantalone K.M., Burguera B. Association of obesity with postacute sequelae of COVID-19. Diabetes Obes Metab. 2021;23(9):2183&#x2013;2188. doi: 10.1111/dom.14454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14454</ArticleId><ArticleId IdType="pmc">PMC8239834</ArticleId><ArticleId IdType="pubmed">34060194</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E., Clohisey S., Klari&#x107; L., et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2020;591(7848):92&#x2013;98. doi: 10.1038/s41586-020-03065-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03065-y</ArticleId><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Xiao J., Sun R., et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis. 2020;26(8):1834&#x2013;1838. doi: 10.3201/eid2608.201097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira C.P.G., Harris B.H.L., Giovannantonio M., et al. The association between antibody response to severe acute respiratory syndrome coronavirus 2 infection and post-COVID-19 syndrome in healthcare workers. J Infect Dis. 2021;223(10):1671&#x2013;1676. doi: 10.1093/infdis/jiab120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab120</ArticleId><ArticleId IdType="pmc">PMC7989400</ArticleId><ArticleId IdType="pubmed">33675366</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M., Gurdasani D., Hamdy A., et al. Uncertainty around the long-term implications of COVID-19. Pathogenetics. 2021;10(10):1267. doi: 10.3390/pathogens10101267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10101267</ArticleId><ArticleId IdType="pmc">PMC8536991</ArticleId><ArticleId IdType="pubmed">34684216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm L.K., Nielsen S.S.F., Pahus M.H., et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021;64 doi: 10.1016/j.ebiom.2021.103230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103230</ArticleId><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Song J., Liu H., Zheng H., Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2020;11(1):10902. doi: 10.2139/ssrn.3555268.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3555268</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S., Cassaniti Irene, Novazzi F., et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2020;104:315&#x2013;319. doi: 10.1016/j.ijid.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A., Engelmann I., Moreau A.S., et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically-ill patients with Covid-19. 2021;51(3):296&#x2013;299. 10.1016/j.idnow.2021.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman V.M., Muth D., Niemeyer D., Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163&#x2013;188. doi: 10.1016/bs.aivir.2018.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.aivir.2018.01.001</ArticleId><ArticleId IdType="pmc">PMC7112090</ArticleId><ArticleId IdType="pubmed">29551135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., Lian X., Su X., et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21(1):224. doi: 10.1186/s12931-020-01479-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01479-w</ArticleId><ArticleId IdType="pmc">PMC7450684</ArticleId><ArticleId IdType="pubmed">32854739</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Zheng B., Zhang Y., Li J. Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Dis Transl Med. 2020;6(2):98&#x2013;105. doi: 10.1016/j.cdtm.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cdtm.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7236734</ArticleId><ArticleId IdType="pubmed">32550040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Timens W., Bulthuis M., et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzikowska U., Ding M., Tan G., et al. Distribution of ACE2, CD147, cyclophilins, CD26 and other SARS-CoV-2 associated molecules in human tissues and immune cells in health and disease. bioRxiv. 2020;75(11):2829-2845 doi: 10.1101/2020.05.14.090332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.14.090332</ArticleId><ArticleId IdType="pmc">PMC7300910</ArticleId><ArticleId IdType="pubmed">32496587</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata-Yoshikawa N., Okamura T., Shimizu Y., et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol. 2019;93(6):e01815&#x2013;e01818. doi: 10.1128/jvi.01815-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01815-18</ArticleId><ArticleId IdType="pmc">PMC6401451</ArticleId><ArticleId IdType="pubmed">30626688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K., Kawase M., Matsuyama S. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology. 2017;517:9&#x2013;15. doi: 10.1016/j.virol.2017.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2017.11.012</ArticleId><ArticleId IdType="pmc">PMC7112029</ArticleId><ArticleId IdType="pubmed">29217279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro J.L. Post-COVID-19 syndrome (PC19S): chronic reactive endotheliitis and disseminated vascular disease. Acta M&#xe9;dica Port. 2020;33(12):859. doi: 10.20344/amp.14612.</Citation><ArticleIdList><ArticleId IdType="doi">10.20344/amp.14612</ArticleId><ArticleId IdType="pubmed">33496258</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S., Garg M., Prabhakar N., Malhotra P., Agarwal R. Unraveling the mystery of Covid-19 Cytokine storm: from skin to organ systems. Dermatol Ther. 2020;33(6):e13859. doi: 10.1111/dth.13859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13859</ArticleId><ArticleId IdType="pmc">PMC7323083</ArticleId><ArticleId IdType="pubmed">32559324</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi F., Qian S., Zhang S., et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. bioRxiv. 2020;526(1):135&#x2013;140. doi: 10.1101/2020.02.16.951913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.16.951913</ArticleId><ArticleId IdType="pmc">PMC7156119</ArticleId><ArticleId IdType="pubmed">32199615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W., Huang N., Becavin C., et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. ArXiv Cell Behav. 2020;26(5):681&#x2013;687. doi: 10.1038/s41591-020-0868-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler C.G.K., Allon S.J., Nyquist S.J., et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. 2020;181(5):1016. 10.2139/ssrn.3555145</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3555145</ArticleId><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W., Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020;30(5):367&#x2013;369. doi: 10.1038/s41422-020-0327-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0327-4</ArticleId><ArticleId IdType="pmc">PMC7186532</ArticleId><ArticleId IdType="pubmed">32346073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashary N., Bhide A., Chakraborty P., et al. Single-cell RNA-seq identifies cell subsets in human placenta that highly expresses factors driving pathogenesis of SARS-CoV-2. 2020;8:783. 10.20944/preprints202005.0195.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.20944/preprints202005.0195.v1</ArticleId><ArticleId IdType="pmc">PMC7466449</ArticleId><ArticleId IdType="pubmed">32974340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Liu Y., Wang X., et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol OncolJ Hematol Oncol. 2020;13(1):1&#x2013;22. doi: 10.1186/s13045-020-00954-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-020-00954-7</ArticleId><ArticleId IdType="pmc">PMC7471641</ArticleId><ArticleId IdType="pubmed">32887634</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurich A., Hofmann-Winkler H., Gierer S., et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88(2):1293&#x2013;1307. doi: 10.1128/jvi.02202-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02202-13</ArticleId><ArticleId IdType="pmc">PMC3911672</ArticleId><ArticleId IdType="pubmed">24227843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram S., Dijkman R., Habjan M., et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol. 2013;87(11):6150&#x2013;6160. doi: 10.1128/jvi.03372-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.03372-12</ArticleId><ArticleId IdType="pmc">PMC3648130</ArticleId><ArticleId IdType="pubmed">23536651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierer S., Bertram S., Kaup F., et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol. 2013;87(10):5502&#x2013;5511. doi: 10.1128/jvi.00128-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00128-13</ArticleId><ArticleId IdType="pmc">PMC3648152</ArticleId><ArticleId IdType="pubmed">23468491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei C., Qian K., Li T., et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11(1):2070. doi: 10.1038/s41467-020-16048-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16048-4</ArticleId><ArticleId IdType="pmc">PMC7265355</ArticleId><ArticleId IdType="pubmed">32332765</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang Y., Wu L., et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894&#x2013;904.e9. doi: 10.1016/j.cell.2020.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680&#x2013;692. doi: 10.1016/j.immuni.2011.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.05.003</ArticleId><ArticleId IdType="pmc">PMC3177755</ArticleId><ArticleId IdType="pubmed">21616437</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20(1):197&#x2013;216. doi: 10.1146/annurev.immunol.20.083001.084359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.20.083001.084359</ArticleId><ArticleId IdType="pubmed">11861602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaleuskaya L.L., Veltrop R., Ikpeze N., et al. Protective role of toll-like receptor 3-induced type I interferon in murine coronavirus infection of macrophages. Viruses. 2012;4(5):901&#x2013;923. doi: 10.3390/v4050901.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4050901</ArticleId><ArticleId IdType="pmc">PMC3386628</ArticleId><ArticleId IdType="pubmed">22754655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur S. Double-stranded RNA sensors and modulators in innate immunity. Annu Rev Immunol. 2019;37(1):349&#x2013;375. doi: 10.1146/annurev-immunol-042718-041356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-042718-041356</ArticleId><ArticleId IdType="pmc">PMC7136661</ArticleId><ArticleId IdType="pubmed">30673536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribero M.S., Jouvenet N., Dreux M., Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLOS Pathog. 2020;16(7) doi: 10.1371/journal.ppat.1008737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008737</ArticleId><ArticleId IdType="pmc">PMC7390284</ArticleId><ArticleId IdType="pubmed">32726355</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36&#x2013;49. doi: 10.1038/nri3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabo S., Meurs E.F. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses. 2012;4(11):2598&#x2013;2635. doi: 10.3390/v4112598.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4112598</ArticleId><ArticleId IdType="pmc">PMC3509664</ArticleId><ArticleId IdType="pubmed">23202496</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Hackbart M., Mettelman R.C., et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci U S A. 2017;114(21) doi: 10.1073/pnas.1618310114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1618310114</ArticleId><ArticleId IdType="pmc">PMC5448190</ArticleId><ArticleId IdType="pubmed">28484023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Cai H., Pan J.A., et al. Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci U S A. 2009;106(9):3484&#x2013;3489. doi: 10.1073/pnas.0808790106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0808790106</ArticleId><ArticleId IdType="pmc">PMC2651275</ArticleId><ArticleId IdType="pubmed">19208801</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieman M.B., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-&#x3ba;B signaling. J Virol. 2009;83(13):6689&#x2013;6705. doi: 10.1128/jvi.02220-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02220-08</ArticleId><ArticleId IdType="pmc">PMC2698564</ArticleId><ArticleId IdType="pubmed">19369340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamitani W., Narayanan K., Huang C., et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci U S A. 2006;103(34):12885&#x2013;12890. doi: 10.1073/pnas.0603144103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0603144103</ArticleId><ArticleId IdType="pmc">PMC1568942</ArticleId><ArticleId IdType="pubmed">16912115</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C.S., Qi H.Y., Boularan C., et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol. 2014;193(6):3080&#x2013;3089. doi: 10.4049/jimmunol.1303196.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1303196</ArticleId><ArticleId IdType="pmc">PMC4179872</ArticleId><ArticleId IdType="pubmed">25135833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopecky-Bromberg S.A., Mart&#xed;nez-Sobrido L., Frieman M.B., Baric R.A., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81(2):548&#x2013;557. doi: 10.1128/jvi.01782-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01782-06</ArticleId><ArticleId IdType="pmc">PMC1797484</ArticleId><ArticleId IdType="pubmed">17108024</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieman M.B., Yount B., Heise M.T., et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol. 2007;81(18):9812&#x2013;9824. doi: 10.1128/jvi.01012-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01012-07</ArticleId><ArticleId IdType="pmc">PMC2045396</ArticleId><ArticleId IdType="pubmed">17596301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang S.F., Lin T.Y., Chow K.C., et al. SARS spike protein induces phenotypic conversion of human B cells to macrophage-like cells. Mol Immunol. 2010;47(16):2575&#x2013;2586. doi: 10.1016/j.molimm.2010.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2010.06.014</ArticleId><ArticleId IdType="pmc">PMC7112600</ArticleId><ArticleId IdType="pubmed">20667598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokol C.L., Luster A.D. The Chemokine System in innate immunity. Cold Spring Harb Perspect Biol. 2015;7(5):a016303. doi: 10.1101/cshperspect.a016303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016303</ArticleId><ArticleId IdType="pmc">PMC4448619</ArticleId><ArticleId IdType="pubmed">25635046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Diao B., Wang R., et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. 2020 doi: 10.1101/2020.03.27.20045427. preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.27.20045427</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N., Britton G.J., Gruber C., et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910&#x2013;941. doi: 10.1016/j.immuni.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., Aschenbrenner A.C. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671&#x2013;1692. doi: 10.1016/j.cell.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. 2020;54:62&#x2013;75. 10.1016/j.cytogfr.2020.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529&#x2013;539. doi: 10.1007/s00281-017-0629-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0629-x</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.J., Su I.J., Theron M., et al. An interferon-&#x3b3;-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185&#x2013;194. doi: 10.1002/jmv.20255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20255</ArticleId><ArticleId IdType="pmc">PMC7166886</ArticleId><ArticleId IdType="pubmed">15602737</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Cheng Y., Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266&#x2013;271. doi: 10.1007/s12250-020-00207-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00207-4</ArticleId><ArticleId IdType="pmc">PMC7090474</ArticleId><ArticleId IdType="pubmed">32125642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen S.F., Ho Y.C. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202&#x2013;2205. doi: 10.1172/jci137647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci137647</ArticleId><ArticleId IdType="pmc">PMC7190904</ArticleId><ArticleId IdType="pubmed">32217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Fu B., Zheng X., et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998&#x2013;1002. doi: 10.1093/nsr/nwaa041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa041</ArticleId><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Guo R., Lei L., et al. COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome. medRxiv. 2020 doi: 10.1101/2020.03.24.20042655. preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.24.20042655</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355&#x2013;362. doi: 10.1038/s41577-020-0331-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams M., Mildner A., Yona S. Developmental and functional heterogeneity of monocytes. Immunity. 2018;49(4):595&#x2013;613. doi: 10.1016/j.immuni.2018.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.10.005</ArticleId><ArticleId IdType="pubmed">30332628</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin L.M., Stamatiades E.G., Auffray C., et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell. 2013;153(2):362&#x2013;375. doi: 10.1016/j.cell.2013.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.03.010</ArticleId><ArticleId IdType="pmc">PMC3898614</ArticleId><ArticleId IdType="pubmed">23582326</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintar A.A., McArdle S., Wolf D., et al. Endothelial protective monocyte patrolling in large arteries intensified by western diet and atherosclerosis. Circ Res. 2017;120(11):1789&#x2013;1799. doi: 10.1161/circresaha.117.310739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.117.310739</ArticleId><ArticleId IdType="pmc">PMC5446289</ArticleId><ArticleId IdType="pubmed">28302649</ArticleId></ArticleIdList></Reference><Reference><Citation>Auffray C., Fogg D.K., Garfa M., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666&#x2013;670. doi: 10.1126/science.1142883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1142883</ArticleId><ArticleId IdType="pubmed">17673663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cros J., Cagnard N., Wollard K., et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375&#x2013;386. doi: 10.1016/j.immuni.2010.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.08.012</ArticleId><ArticleId IdType="pmc">PMC3063338</ArticleId><ArticleId IdType="pubmed">20832340</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle S., Chodaczek G., Ray N., Ley K. Intravital live cell triggered imaging system reveals monocyte patrolling and macrophage migration in atherosclerotic arteries. J Biomed Opt. 2015;20(2) doi: 10.1117/1.jbo.20.2.026005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.jbo.20.2.026005</ArticleId><ArticleId IdType="pmc">PMC4339534</ArticleId><ArticleId IdType="pubmed">25710308</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcovecchio P., Thomas G.D., Mikulski Z., et al. Scavenger receptor CD36 directs nonclassical monocyte patrolling along the endothelium during early atherogenesis. Arterioscler Thromb Vasc Biol. 2017;37(11):2043&#x2013;2052. doi: 10.1161/atvbaha.117.309123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/atvbaha.117.309123</ArticleId><ArticleId IdType="pmc">PMC5930003</ArticleId><ArticleId IdType="pubmed">28935758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacke F., Alvarez D., Kaplan T.J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117(1):185&#x2013;194. doi: 10.1172/jci28549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci28549</ArticleId><ArticleId IdType="pmc">PMC1716202</ArticleId><ArticleId IdType="pubmed">17200718</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollard K.J., Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7(2):77&#x2013;86. doi: 10.1038/nrcardio.2009.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2009.228</ArticleId><ArticleId IdType="pmc">PMC2813241</ArticleId><ArticleId IdType="pubmed">20065951</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x10c;ejkov&#xe1; S., Kr&#xe1;lov&#xe1;-Lesn&#xe1; I., Poledne R. Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development. Cor Vasa. 2016;58(4):467&#x2013;473. doi: 10.1016/j.crvasa.2015.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crvasa.2015.08.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna R.N., Shaked I., Hubbeling H.G., et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res. 2012;110(3):416&#x2013;427. doi: 10.1161/circresaha.111.253377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.111.253377</ArticleId><ArticleId IdType="pmc">PMC3309661</ArticleId><ArticleId IdType="pubmed">22194622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.W., Zhang P., Yang J.Y., et al. Nur77 decreases atherosclerosis progression in apoE&#x2212;/&#x2212; mice fed a high-fat/high-cholesterol diet. PLoS One. 2014;9(1):e87313. doi: 10.1371/journal.pone.0087313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087313</ArticleId><ArticleId IdType="pmc">PMC3909091</ArticleId><ArticleId IdType="pubmed">24498071</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J., et al. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623(7985):139&#x2013;148. doi: 10.1101/2022.08.09.22278592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao L.C., Soto E., Hong C., et al. Bone marrow NR4A expression is not a dominant factor in the development of atherosclerosis or macrophage polarization in mice. J Lipid Res. 2013;54(3):806&#x2013;815. doi: 10.1194/jlr.m034157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.m034157</ArticleId><ArticleId IdType="pmc">PMC3617954</ArticleId><ArticleId IdType="pubmed">23288947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei L., Castrillo A., Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol. 2006;20(4):786&#x2013;794. doi: 10.1210/me.2005-0331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2005-0331</ArticleId><ArticleId IdType="pubmed">16339277</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Huang L., Sung S.S.J., et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia&#x2013;reperfusion injury. Kidney Int. 2008;74(12):1526&#x2013;1537. doi: 10.1038/ki.2008.500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2008.500</ArticleId><ArticleId IdType="pmc">PMC2652647</ArticleId><ArticleId IdType="pubmed">18843253</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasawa K., Asano K., Moriyama S., et al. Vascular-resident CD169-positive monocytes and macrophages control neutrophil accumulation in the kidney with ischemia-reperfusion injury. J Am Soc Nephrol. 2015;26(4):896&#x2013;906. doi: 10.1681/asn.2014020195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.2014020195</ArticleId><ArticleId IdType="pmc">PMC4378108</ArticleId><ArticleId IdType="pubmed">25266072</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahrendorf M., Swirski F.K., Aikawa E., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037&#x2013;3047. doi: 10.1084/jem.20070885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20070885</ArticleId><ArticleId IdType="pmc">PMC2118517</ArticleId><ArticleId IdType="pubmed">18025128</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgendorf I., Gerhardt L.M.S., Tan T.C., et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ Res. 2014;114(10):1611&#x2013;1622. doi: 10.1161/circresaha.114.303204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.114.303204</ArticleId><ArticleId IdType="pmc">PMC4017349</ArticleId><ArticleId IdType="pubmed">24625784</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterbusch M., Hall Pam, Li A., et al. Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus. Proc Natl Acad Sci U S A. 2016;113(35) doi: 10.1073/pnas.1606253113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1606253113</ArticleId><ArticleId IdType="pmc">PMC5024581</ArticleId><ArticleId IdType="pubmed">27528685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Hu F., Sun X., et al. CD16+ monocyte subset was enriched and functionally exacerbated in driving T-cell activation and B-cell response in systemic lupus erythematosus. Front Immunol. 2016;7:512. doi: 10.3389/fimmu.2016.00512.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00512</ArticleId><ArticleId IdType="pmc">PMC5116853</ArticleId><ArticleId IdType="pubmed">27917174</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a A.B., G&#xf3;mez-Puerta J.A., Arias L.F., et al. Infiltrating CD16+ are associated with a reduction in peripheral CD14+CD16++ monocytes and severe forms of lupus nephritis. Autoimmune Dis. 2016;2016 doi: 10.1155/2016/9324315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9324315</ArticleId><ArticleId IdType="pmc">PMC5187455</ArticleId><ArticleId IdType="pubmed">28070418</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee R., Barman P.K., Thatoi P.K., et al. Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematous. Sci Rep. 2015;5(1):13886. doi: 10.1038/srep13886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13886</ArticleId><ArticleId IdType="pmc">PMC4566081</ArticleId><ArticleId IdType="pubmed">26358827</ArticleId></ArticleIdList></Reference><Reference><Citation>Misharin A.V., Cuda C.M., Saber R., et al. Nonclassical Ly6C&#x2212; monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 2014;9(2):591&#x2013;604. doi: 10.1016/j.celrep.2014.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.09.032</ArticleId><ArticleId IdType="pmc">PMC4223808</ArticleId><ArticleId IdType="pubmed">25373902</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchner A., Saferding V., Bonelli M., et al. Non-classical monocytes as mediators of tissue destruction in arthritis. Ann Rheum Dis. 2018;77(10):1490&#x2013;1497. doi: 10.1136/annrheumdis-2018-213250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213250</ArticleId><ArticleId IdType="pmc">PMC6161666</ArticleId><ArticleId IdType="pubmed">29959183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacerte P., Brunet A., Egarnes B., et al. Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists. Arthritis Res Ther. 2016;18(1):10. doi: 10.1186/s13075-015-0901-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0901-1</ArticleId><ArticleId IdType="pmc">PMC4718023</ArticleId><ArticleId IdType="pubmed">26759164</ArticleId></ArticleIdList></Reference><Reference><Citation>Waschbisch A., Schr&#xf6;der S.D., Schraudner D., et al. Pivotal role for CD16+ monocytes in immune surveillance of the central nervous system. J Immunol. 2016;196(4):1558&#x2013;1567. doi: 10.4049/jimmunol.1501960.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501960</ArticleId><ArticleId IdType="pubmed">26746191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjelstrup M.C., Stilund M., Petersen T., et al. Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis. Immunol Cell Biol. 2018;96(2):160&#x2013;174. doi: 10.1111/imcb.1025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.1025</ArticleId><ArticleId IdType="pmc">PMC5836924</ArticleId><ArticleId IdType="pubmed">29363161</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchini M., Duchene J., Santovito D., et al. PD-L1 expression on nonclassical monocytes reveals their origin and immunoregulatory function. Sci Immunol. 2019;4(36):3054. doi: 10.1126/sciimmunol.aar3054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aar3054</ArticleId><ArticleId IdType="pubmed">31227596</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Zhao B., Qu Y., et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis. 2020;71(8):1937&#x2013;1942. doi: 10.1093/cid/ciaa449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa449</ArticleId><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Eldin H.S., Taeimah M., Khattab R.T., Salem R.M. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang Kun, Wang W., et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846&#x2013;848. doi: 10.1007/s00134-020-05991-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506. doi: 10.1016/s0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D.I., Guo W., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620&#x2013;2629. doi: 10.1172/jci137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Li T., Han M., et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791&#x2013;796. doi: 10.1002/jmv.25770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25770</ArticleId><ArticleId IdType="pmc">PMC7228247</ArticleId><ArticleId IdType="pubmed">32181911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Liu H.G., Liu W., et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis. 2020;43(3):203&#x2013;208. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.0005</ArticleId><ArticleId IdType="pubmed">32164089</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2021;118(34):24. doi: 10.1073/pnas.2024358118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratajczak M.Z., Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine &#x201c;storm&#x201d; and risk factor for damage of hematopoietic stem cells. Leukemia. 2020;34(7):1726&#x2013;1729. doi: 10.1038/s41375-020-0887-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0887-9</ArticleId><ArticleId IdType="pmc">PMC7262681</ArticleId><ArticleId IdType="pubmed">32483300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221&#x2013;225. doi: 10.1038/nature09663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09663</ArticleId><ArticleId IdType="pubmed">21124315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratajczak M.Z., Bujko K., Ciechanowicz A., et al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45 - precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 inflammasome. Stem Cell Rev Rep. 2021;17(1):266&#x2013;277. doi: 10.1007/s12015-020-10010-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10010-z</ArticleId><ArticleId IdType="pmc">PMC7370872</ArticleId><ArticleId IdType="pubmed">32691370</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;: a hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol Res Perspect. 2022;10(1):e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Qu R., Junqueira C., et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606(7914):585&#x2013;593. doi: 10.1038/s41586-022-04802-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Broz P., Dixit V.M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407&#x2013;420. doi: 10.1038/nri.2016.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.58</ArticleId><ArticleId IdType="pubmed">27291964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N., Jeltema D., Duan Y., He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi: 10.3390/ijms20133328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133328</ArticleId><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Niles M.A., Gogesch P., Kronhart S., et al. Macrophages and dendritic cells are not the major source of pro-inflammatory cytokines upon SARS-CoV-2 infection. Front Immunol. 2021;12 doi: 10.3389/fimmu.2021.647824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.647824</ArticleId><ArticleId IdType="pmc">PMC8187925</ArticleId><ArticleId IdType="pubmed">34122407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Chu H., Hou Y., et al. Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222(5):734&#x2013;745. doi: 10.1093/infdis/jiaa356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa356</ArticleId><ArticleId IdType="pmc">PMC7337793</ArticleId><ArticleId IdType="pubmed">32563187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojyo S., Uchida M., Tanaka K., et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40(1):37. doi: 10.1186/s41232-020-00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-020-00146-3</ArticleId><ArticleId IdType="pmc">PMC7527296</ArticleId><ArticleId IdType="pubmed">33014208</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumaza A., Gay L., Mezouar S., et al. Monocytes and macrophages, targets of severe acute respiratory syndrome coronavirus 2: the clue for coronavirus disease 2019 immunoparalysis. J Infect Dis. 2021;224(3):395&#x2013;406. doi: 10.1093/infdis/jiab044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab044</ArticleId><ArticleId IdType="pmc">PMC7928817</ArticleId><ArticleId IdType="pubmed">33493287</ArticleId></ArticleIdList></Reference><Reference><Citation>Aymonnier K., Ng J., Fredenburgh L.E., et al. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 2022;6(7):2001&#x2013;2013. doi: 10.1182/bloodadvances.2021005949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005949</ArticleId><ArticleId IdType="pmc">PMC8741335</ArticleId><ArticleId IdType="pubmed">34991159</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello C.A., Ikejima T., Warner S.J., et al. Interleukin 1 induces interleukin 1. I: induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139(6):1902&#x2013;1910. doi: 10.4049/jimmunol.139.6.1902.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.139.6.1902</ArticleId><ArticleId IdType="pubmed">3497982</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner S.J.C., Auger K.R., Libby P. Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol. 1987;139(6):1911&#x2013;1917. doi: 10.4049/jimmunol.139.6.1911.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.139.6.1911</ArticleId><ArticleId IdType="pubmed">3497983</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner S.J.C., Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol. 1989;142(1):100&#x2013;109. doi: 10.4049/jimmunol.142.1.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.142.1.100</ArticleId><ArticleId IdType="pubmed">2783319</ArticleId></ArticleIdList></Reference><Reference><Citation>Loppnow H., Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol. 1989;122(2):493&#x2013;503. doi: 10.1016/0008-8749(89)90095-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0008-8749(89)90095-6</ArticleId><ArticleId IdType="pubmed">2788520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062. doi: 10.1016/s0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponti G., Maccaferri M., Ruini C., Tomasi A., Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389&#x2013;399. doi: 10.1080/10408363.2020.1770685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1770685</ArticleId><ArticleId IdType="pmc">PMC7284147</ArticleId><ArticleId IdType="pubmed">32503382</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans P.C., Rainger G.E., Mason J.C., et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC council of basic cardiovascular science. Cardiovasc Res. 2020;116(14):2177&#x2013;2184. doi: 10.1093/cvr/cvaa230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa230</ArticleId><ArticleId IdType="pmc">PMC7454368</ArticleId><ArticleId IdType="pubmed">32750108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard I., Limonta D., Mahal L.K., Hobman T.C. Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19. Viruses. 2020;13(1):29. doi: 10.3390/v13010029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010029</ArticleId><ArticleId IdType="pmc">PMC7823949</ArticleId><ArticleId IdType="pubmed">33375371</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodor A., Tiperciuc B., Login C., et al. Endothelial dysfunction, inflammation, and oxidative stress in COVID-19-mechanisms and therapeutic targets. Oxid Med Cell Longev. 2021;2021 doi: 10.1155/2021/8671713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8671713</ArticleId><ArticleId IdType="pmc">PMC8397545</ArticleId><ArticleId IdType="pubmed">34457119</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., L&#xfc;scher T.F. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038&#x2013;3044. doi: 10.1093/eurheartj/ehaa623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Libby P., Ridker P.M. COVID-19: a vascular disease. Trends Cardiovasc Med. 2020;31(1):1&#x2013;5. doi: 10.1016/j.tcm.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnhuber A., Fliesser E., Gorkiewicz G., et al. Between inflammation and thrombosis - endothelial cells in COVID-19. Eur Respir J. 2021;58(3) doi: 10.1183/13993003.00377-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00377-2021</ArticleId><ArticleId IdType="pmc">PMC8112008</ArticleId><ArticleId IdType="pubmed">33958433</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung F., Kr&#xfc;ger-Genge A., Franke R.P., Hufert F., K&#xfc;pper J.H. COVID-19 and the endothelium. Clin Hemorheol Microcirc. 2020;75(1):7&#x2013;11. doi: 10.3233/ch-209007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/ch-209007</ArticleId><ArticleId IdType="pmc">PMC7458498</ArticleId><ArticleId IdType="pubmed">32568187</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2013;422. doi: 10.1016/s2213-2600(20)30076-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(20)30076-x</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia M., Zemans R.L., Jeyaseelan S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol. 2012;46(5):566&#x2013;572. doi: 10.1165/rcmb.2011-0392tr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2011-0392tr</ArticleId><ArticleId IdType="pmc">PMC3361356</ArticleId><ArticleId IdType="pubmed">22323365</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., et al. Gross examination report of a COVID-19 death autopsy. 2020;36(1):21&#x2013;23. 10.12116/j.issn.1004-5619.2020.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.12116/j.issn.1004-5619.2020.01.005</ArticleId><ArticleId IdType="pubmed">32198987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Liu L., Zhang D., et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517&#x2013;1520. doi: 10.1016/s0140-6736(20)30920-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30920-x</ArticleId><ArticleId IdType="pmc">PMC7164875</ArticleId><ArticleId IdType="pubmed">32311318</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020;395(10234):1417&#x2013;1418. doi: 10.1016/s0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S., Qin M., Shen B., et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802&#x2013;810. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Driggin E., Madhavan M.V., Bikdeli B., et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352&#x2013;2371. doi: 10.1016/j.jacc.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7198856</ArticleId><ArticleId IdType="pubmed">32201335</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerkin K.J., Fried J., Raikhelkar J., et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648&#x2013;1655. doi: 10.1161/circulationaha.120.046941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.120.046941</ArticleId><ArticleId IdType="pubmed">32200663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259&#x2013;260. doi: 10.1038/s41569-020-0360-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0360-5</ArticleId><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798&#x2013;1800. doi: 10.1093/eurheartj/ehaa231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa231</ArticleId><ArticleId IdType="pmc">PMC7454513</ArticleId><ArticleId IdType="pubmed">32186331</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Fan Y., Chen M., et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(7):811&#x2013;818. doi: 10.1001/jamacardio.2020.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Luo R., Wang K., et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829&#x2013;838. doi: 10.1016/j.kint.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7110296</ArticleId><ArticleId IdType="pubmed">32247631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209&#x2013;218. doi: 10.1016/j.kint.2020.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7229463</ArticleId><ArticleId IdType="pubmed">32416116</ArticleId></ArticleIdList></Reference><Reference><Citation>Albornoz E.A., Amarilla A.A., Modhiran N., et al. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. 2023;28(7):2878&#x2013;2893. doi: 10.1038/s41380-022-01831-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01831-0</ArticleId><ArticleId IdType="pmc">PMC10615762</ArticleId><ArticleId IdType="pubmed">36316366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta D., Liu J., Xiong H. NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes. Int J Physiol Pathophysiol Pharmacol. 2022;14(3):138&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301183</ArticleId><ArticleId IdType="pubmed">35891930</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckheeram R.V., Zhou R., Verma A.D., Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol. 2012;2012 doi: 10.1155/2012/925135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/925135</ArticleId><ArticleId IdType="pmc">PMC3312336</ArticleId><ArticleId IdType="pubmed">22474485</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489&#x2013;1501. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Sidney J., Kidd C.K., et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021;2(2) doi: 10.1016/j.xcrm.2021.100204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100204</ArticleId><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V., Denolly S., Vogrig M., et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318&#x2013;327. doi: 10.1038/s41423-020-00588-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pmc">PMC7786875</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S., Falk A.J., Klingstr&#xf6;m J., et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLOS ONE. 2022;17(1) doi: 10.1371/journal.pone.0262169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262169</ArticleId><ArticleId IdType="pmc">PMC8754314</ArticleId><ArticleId IdType="pubmed">35020778</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L., Park Y.J., Tortorici M.A., et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024. doi: 10.1016/j.cell.2020.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai K., Matsuoka M., Tabata S., et al. Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities. Int J Infect Dis. 2021;111:68&#x2013;75. doi: 10.1016/j.ijid.2021.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.08.026</ArticleId><ArticleId IdType="pmc">PMC8364517</ArticleId><ArticleId IdType="pubmed">34407480</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D., Weng T., Wu J., et al. Dynamic characteristic analysis of antibodies in patients with COVID-19: a 13-month study. Front Immunol. 2021;12 doi: 10.3389/fimmu.2021.708184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.708184</ArticleId><ArticleId IdType="pmc">PMC8330131</ArticleId><ArticleId IdType="pubmed">34354712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthar M.S., Zimmerman M.G., Kauffman R.C., et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3) doi: 10.1016/j.xcrm.2020.100040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100040</ArticleId><ArticleId IdType="pmc">PMC7276302</ArticleId><ArticleId IdType="pubmed">32835303</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinti I., Mortari E.P., Fernandez Salinas A., Milito C., Carsetti R. IgA antibodies and IgA deficiency in SARS-CoV-2 infection. Front Cell Infect Microbiol. 2021;11 doi: 10.3389/fcimb.2021.655896.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.655896</ArticleId><ArticleId IdType="pmc">PMC8057809</ArticleId><ArticleId IdType="pubmed">33889552</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar T., Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol. 2020;20(7):392&#x2013;394. doi: 10.1038/s41577-020-0359-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0359-5</ArticleId><ArticleId IdType="pmc">PMC7278217</ArticleId><ArticleId IdType="pubmed">32514035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuri-Cervantes L., Pampena M.B., Meng W., et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5(49):eabd7114. doi: 10.1126/sciimmunol.abd7114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd7114</ArticleId><ArticleId IdType="pmc">PMC7402634</ArticleId><ArticleId IdType="pubmed">32669287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A., Salvati L., Maggi L., et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694&#x2013;4703. doi: 10.1172/jci138554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci138554</ArticleId><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Varchetta S., Mele D., Oliviero B., et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol. 2020;18(3):604&#x2013;612. doi: 10.1038/s41423-020-00557-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00557-9</ArticleId><ArticleId IdType="pmc">PMC7557230</ArticleId><ArticleId IdType="pubmed">33060840</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B., Wang C., Tan Y., et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Modabber Z., Shahbazi M., Akbari R., et al. TIM-3 as a potential exhaustion marker in CD4 + T cells of COVID-19 patients. Immun Inflamm Dis. 2021;9(4):1707&#x2013;1715. doi: 10.1002/iid3.526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.526</ArticleId><ArticleId IdType="pmc">PMC8589347</ArticleId><ArticleId IdType="pubmed">34499819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusnadi A., Ram&#xed;rez-Su&#xe1;stegui C., Fajardo V., et al. Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8 + T cells. Sci Immunol. 2021;6(55):eabe4782. doi: 10.1126/sciimmunol.abe4782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe4782</ArticleId><ArticleId IdType="pmc">PMC8101257</ArticleId><ArticleId IdType="pubmed">33478949</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo S., Chevrier S., Cervia C., et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy. 2021;76(9):2866&#x2013;2881. doi: 10.1111/all.14866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14866</ArticleId><ArticleId IdType="pmc">PMC8251365</ArticleId><ArticleId IdType="pubmed">33884644</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Gao Yong, Wang G., et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533&#x2013;535. doi: 10.1038/s41423-020-0402-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36(6) doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton G., Mendoza P., H&#xe4;ggl&#xf6;f T., et al. Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med. 2021;218(4) doi: 10.1084/jem.20202515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202515</ArticleId><ArticleId IdType="pmc">PMC7845919</ArticleId><ArticleId IdType="pubmed">33533915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring A.S., Hodcroft E.B. Genetic variants of SARS-CoV-2&#x2014;what do they mean? JAMA. 2021;325(6):529. doi: 10.1001/jama.2020.27124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.27124</ArticleId><ArticleId IdType="pubmed">33404586</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio S., Martignano F., Torcia M.G., Mattiuz G., Conticello S.G. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv. 2020;6(25):eabb5813. doi: 10.1126/sciadv.abb5813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb5813</ArticleId><ArticleId IdType="pmc">PMC7299625</ArticleId><ArticleId IdType="pubmed">32596474</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter J.D., Bennett R.P., Smith H.C. The APOBEC protein family: united by structure, divergent in function. Trends Biochem Sci. 2016;41(7):578&#x2013;594. doi: 10.1016/j.tibs.2016.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2016.05.001</ArticleId><ArticleId IdType="pmc">PMC4930407</ArticleId><ArticleId IdType="pubmed">27283515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.D.Y., Kim T.T.Y., Walsh T., et al. Widespread RNA editing of embedded Alu elements in the human transcriptome. Genome Res. 2004;14(9):1719&#x2013;1725. doi: 10.1101/gr.2855504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.2855504</ArticleId><ArticleId IdType="pmc">PMC515317</ArticleId><ArticleId IdType="pubmed">15342557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourier T., Sadykov M., Carr M.J., Gonzalez G., Hall W.W., Pain A. Host-directed editing of the SARS-CoV-2 genome. Biochem Biophys Res Commun. 2021;538:35&#x2013;39. doi: 10.1016/j.bbrc.2020.10.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.092</ArticleId><ArticleId IdType="pmc">PMC7643664</ArticleId><ArticleId IdType="pubmed">33234239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P., Barmania F., Mellet J., et al. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2022;12 doi: 10.3389/fimmu.2021.809244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.809244</ArticleId><ArticleId IdType="pmc">PMC8761766</ArticleId><ArticleId IdType="pubmed">35046961</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. COVID-19 weekly epidemiological update. Special edition: proposed working definitions of SARS-CoV-2 variants of interest and variants of concern. Available at:Https://Www.Who.Int/Publications/m/Item/Covid-19-Weekly-Epidemiological-Update.</Citation></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205&#x2013;1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech C.B., Walker S.C., Samuels R.J. SARS-CoV-2 vaccines. JAMA. 2021;325(13):1318. doi: 10.1001/jama.2021.3199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3199</ArticleId><ArticleId IdType="pubmed">33635317</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.Y., Smith D.M. SARS-CoV-2 variants of concern. Yonsei Med J. 2021;62(11):961. doi: 10.3349/ymj.2021.62.11.961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2021.62.11.961</ArticleId><ArticleId IdType="pmc">PMC8542474</ArticleId><ArticleId IdType="pubmed">34672129</ArticleId></ArticleIdList></Reference><Reference><Citation>Telenti A., Hodcroft E.B., Robertson D.L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12(5) doi: 10.1101/cshperspect.a041390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a041390</ArticleId><ArticleId IdType="pmc">PMC9159258</ArticleId><ArticleId IdType="pubmed">35444005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K., Tzou P.L., Nouhin J., et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757&#x2013;773. doi: 10.1038/s41576-021-00408-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00408-x</ArticleId><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., Holmes E.C., &#xc1; O'Toole, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5(11):1403&#x2013;1407. doi: 10.1038/s41564-020-0770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya J.M., Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci. 2007;1108(1):567&#x2013;577. doi: 10.1196/annals.1422.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1422.059</ArticleId><ArticleId IdType="pubmed">17894021</ArticleId></ArticleIdList></Reference><Reference><Citation>Maya R., Gershwin M.E., Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol. 2008;34(1):85&#x2013;102. doi: 10.1007/s12016-007-8013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-007-8013-6</ArticleId><ArticleId IdType="pubmed">18270862</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller S., Boire G., Ossondo M., et al. IgG autoantibody response in HTLV-I-infected patients. Clin Immunol Immunopathol. 1995;77(3):282&#x2013;290. doi: 10.1006/clin.1995.1154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1995.1154</ArticleId><ArticleId IdType="pubmed">7586738</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller S., Richalet P., Laurent-Crawford A.G., et al. Autoantibodies typical of non-organ-specific autoimmune diseases in HIV-seropositive patients. AIDS. 1992;6(9):933&#x2013;942. doi: 10.1097/00002030-199209000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-199209000-00004</ArticleId><ArticleId IdType="pubmed">1388904</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilopoulos A.N., Dummer W., Kono D.H. T cell homeostasis and systemic autoimmunity. J Clin Invest. 2001;108(3):335&#x2013;340. doi: 10.1172/jci12173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci12173</ArticleId><ArticleId IdType="pmc">PMC209358</ArticleId><ArticleId IdType="pubmed">11489923</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762&#x2013;768. doi: 10.1093/cid/ciaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujinami R.S., von Herrath M., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80&#x2013;94. doi: 10.1128/cmr.19.1.80-94.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.19.1.80-94.2006</ArticleId><ArticleId IdType="pmc">PMC1360274</ArticleId><ArticleId IdType="pubmed">16418524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M., Tincani A., Andreoli L., et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8) doi: 10.1016/j.autrev.2020.102597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102597</ArticleId><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4) doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasaraju T., Tang B., Herrmann M., Muller S., Chow V.T.K., Radic M.Z. Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19. Front Pharmacol. 2020;11(11):870. doi: 10.3389/fphar.2020.00870.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00870</ArticleId><ArticleId IdType="pmc">PMC7291833</ArticleId><ArticleId IdType="pubmed">32581816</ArticleId></ArticleIdList></Reference><Reference><Citation>Apel Falko, Apel F., Zychlinsky A., Kenny E.F. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol. 2018;14(8):467&#x2013;475. doi: 10.1038/s41584-018-0039-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0039-z</ArticleId><ArticleId IdType="pubmed">29930301</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz-Agranov N., Zandman-Goddard G. Autoimmunity and COVID-19: the microbiotal connection. Autoimmun Rev. 2021;20(8) doi: 10.1016/j.autrev.2021.102865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102865</ArticleId><ArticleId IdType="pmc">PMC8189735</ArticleId><ArticleId IdType="pubmed">34118455</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes V., Galv&#xe3;o I., Vieira A.T. Mechanisms by which the gut microbiota influences cytokine production and modulates host inflammatory responses. J Interferon Cytokine Res. 2019;39(7):393&#x2013;409. doi: 10.1089/jir.2019.0011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2019.0011</ArticleId><ArticleId IdType="pubmed">31013453</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow J., Tang H., Mazmanian S.K. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol. 2011;23(4):473&#x2013;480. doi: 10.1016/j.coi.2011.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2011.07.010</ArticleId><ArticleId IdType="pmc">PMC3426444</ArticleId><ArticleId IdType="pubmed">21856139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Liu Q., Zhang F., et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2020;70(2):276&#x2013;284. doi: 10.1136/gutjnl-2020-322294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322294</ArticleId><ArticleId IdType="pmc">PMC7385744</ArticleId><ArticleId IdType="pubmed">32690600</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside T.L., De Luca F., Shoenfeld Y., Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195(1):74&#x2013;85. doi: 10.1111/cei.13158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13158</ArticleId><ArticleId IdType="pmc">PMC6300652</ArticleId><ArticleId IdType="pubmed">29920643</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira-Ros&#xe1;rio A., Marques C., Pinheiro H., et al. Gut microbiota diversity and c-reactive protein are predictors of disease severity in COVID-19 patients. Front Microbiol. 2021;12 doi: 10.3389/fmicb.2021.705020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.705020</ArticleId><ArticleId IdType="pmc">PMC8326578</ArticleId><ArticleId IdType="pubmed">34349747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi G., Giovanetti M., Benedetti F., et al. Gut microbiota and COVID-19: potential implications for disease severity. Pathogens. 2022;11(9):1050. doi: 10.3390/pathogens11091050.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11091050</ArticleId><ArticleId IdType="pmc">PMC9503814</ArticleId><ArticleId IdType="pubmed">36145482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Sharma A.R., Bhattacharya M., Dhama K., Lee S.S. Altered gut microbiota patterns in COVID-19: markers for inflammation and disease severity. World J Gastroenterol. 2022;28(25):2802&#x2013;2822. doi: 10.3748/wjg.v28.i25.2802.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i25.2802</ArticleId><ArticleId IdType="pmc">PMC9280735</ArticleId><ArticleId IdType="pubmed">35978881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas Manuel, Rodr&#xed;guez Y., Acosta-Ampudia Y., et al. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20(1):129. doi: 10.1186/s12967-022-03328-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolini S., Vannini A., Deleonardi G., et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2020;14(2):502&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536986</ArticleId><ArticleId IdType="pubmed">32989903</ArticleId></ArticleIdList></Reference><Reference><Citation>Trahtemberg U., Rottapel R., dos Santos CC, et al. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis. 2021;80(9):1236&#x2013;1240. doi: 10.1136/annrheumdis-2021-220206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220206</ArticleId><ArticleId IdType="pmc">PMC8076626</ArticleId><ArticleId IdType="pubmed">33903092</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha M., Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021;7(2) doi: 10.1136/rmdopen-2021-001580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001580</ArticleId><ArticleId IdType="pmc">PMC8103564</ArticleId><ArticleId IdType="pubmed">33958439</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeano-Valle F., Oblitas C.M., Ferreiro-Maz&#xf3;n M.M., et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113&#x2013;115. doi: 10.1016/j.thromres.2020.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.05.017</ArticleId><ArticleId IdType="pmc">PMC7227496</ArticleId><ArticleId IdType="pubmed">32425261</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost. 2006;4(2):295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghilardi G., Kessler C., Colucci G., et al. Long-term evaluation of antiphospholipid antibodies in patients with COVID-19. Preprints with The Lancet. 2021 doi: 10.2139/ssrn.3781640. preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3781640</ArticleId></ArticleIdList></Reference><Reference><Citation>Blickstein D., Izak M., Filipovich- Rimon T., et al. P1622: antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID-19. HemaSphere. 2022;6:1503&#x2013;1504. doi: 10.1097/01.hs9.0000849344.70911.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.hs9.0000849344.70911.19</ArticleId><ArticleId IdType="pubmed">37191363</ArticleId></ArticleIdList></Reference><Reference><Citation>Uthman I., Gharavi A.E. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002;31(4):256&#x2013;263. doi: 10.1053/sarh.2002.28303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/sarh.2002.28303</ArticleId><ArticleId IdType="pubmed">11836658</ArticleId></ArticleIdList></Reference><Reference><Citation>Almashat S.A. Vasculitis in COVID-19: a literature review. 2020;6(1):1&#x2013;5. doi: 10.37421/j.</Citation><ArticleIdList><ArticleId IdType="doi">10.37421/j</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns J.C., Herzog L., Fabri O., et al. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9) doi: 10.1371/journal.pone.0074529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074529</ArticleId><ArticleId IdType="pmc">PMC3776809</ArticleId><ArticleId IdType="pubmed">24058585</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns J.C., Cayan D.R., Tong G., et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology. 2005;16(2):220&#x2013;225. doi: 10.1097/01.ede.0000152901.06689.d4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ede.0000152901.06689.d4</ArticleId><ArticleId IdType="pmc">PMC2894624</ArticleId><ArticleId IdType="pubmed">15703537</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara R., Belay E.D. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012;22(2):79&#x2013;85. doi: 10.2188/jea.je20110131.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.je20110131</ArticleId><ArticleId IdType="pmc">PMC3798585</ArticleId><ArticleId IdType="pubmed">22307434</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirfakhryan H. Kawasaki-like disease in children with COVID-19: a hypothesis. Med Hypotheses. 2020;143 doi: 10.1016/j.mehy.2020.110117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110117</ArticleId><ArticleId IdType="pmc">PMC7367792</ArticleId><ArticleId IdType="pubmed">32721809</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley A.H., Wylie K.M., Kim K.Y., et al. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics. 2015;16(1):1076. doi: 10.1186/s12864-015-2323-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-015-2323-5</ArticleId><ArticleId IdType="pmc">PMC4683744</ArticleId><ArticleId IdType="pubmed">26679344</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Aravamudan V.M., Sridharan G.K., et al. Kawasaki like illness due to COVID-19: a review of the literature. J Infect Dev Ctries. 2021;15(5):630&#x2013;638. doi: 10.3855/jidc.14185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.14185</ArticleId><ArticleId IdType="pubmed">34106885</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Oharaseki T., Naoe S., Wakayama M., Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005;47(3):305&#x2013;310. doi: 10.1111/j.1442-200x.2005.02049.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-200x.2005.02049.x</ArticleId><ArticleId IdType="pubmed">15910456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Schulte D.J., Shimada K., et al. Interleukin-1&#x3b2; is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125(12):1542&#x2013;1550. doi: 10.1161/circulationaha.111.072769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.111.072769</ArticleId><ArticleId IdType="pmc">PMC3337219</ArticleId><ArticleId IdType="pubmed">22361326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai T., Ishiwata T., Kobayashi T., et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease a retrospective study. Circulation. 2011;124(25):2822&#x2013;2828. doi: 10.1161/circulationaha.111.028423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.111.028423</ArticleId><ArticleId IdType="pubmed">22104548</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogan P.A., Burns J.C., Cornish J., et al. Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart. 2020;106(6):411&#x2013;420. doi: 10.1136/heartjnl-2019-315925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2019-315925</ArticleId><ArticleId IdType="pmc">PMC7057818</ArticleId><ArticleId IdType="pubmed">31843876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouldali N., Pouletty M., Mariani P., et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health. 2020;4(9):662&#x2013;668. doi: 10.1016/S2352-4642(20)30175-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30175-9</ArticleId><ArticleId IdType="pmc">PMC7332278</ArticleId><ArticleId IdType="pubmed">32622376</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni L., Mazza A., Gervasoni A., et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771&#x2013;1778. doi: 10.1016/s0140-6736(20)31103-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31103-x</ArticleId><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Algarni A.S., Alamri N.M., Khayat N.Z., et al. Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. World J Pediatr. 2022;18(2):83&#x2013;90. doi: 10.1007/s12519-021-00499-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-021-00499-w</ArticleId><ArticleId IdType="pmc">PMC8725428</ArticleId><ArticleId IdType="pubmed">34982402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravelli A., Martini A. Kawasaki disease or Kawasaki syndrome. Ann Rheum Dis. 2020;79(8):993&#x2013;995. doi: 10.1136/annrheumdis-2020-218110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218110</ArticleId><ArticleId IdType="pmc">PMC7335693</ArticleId><ArticleId IdType="pubmed">32571869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiew F.L., Ramlan R., Viswanathan S., Puvanarajah S.D. Guillain-Barr&#xe9; Syndrome, variants &amp; forms fruste: reclassification with new criteria. Clin Neurol Neurosurg. 2017;158:114&#x2013;118. doi: 10.1016/j.clineuro.2017.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2017.05.006</ArticleId><ArticleId IdType="pubmed">28514704</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimachkie M.M., Barohn R.J. Guillain-Barr&#xe9; syndrome and variants. Neurol Clin. 2013;31(2):491&#x2013;510. doi: 10.1016/j.ncl.2013.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2013.01.005</ArticleId><ArticleId IdType="pmc">PMC3939842</ArticleId><ArticleId IdType="pubmed">23642721</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrogan A., Madle G., Seaman H., de Vries C.S. The epidemiology of Guillain-Barre syndrome worldwide a systematic literature review. Neuroepidemiology. 2009;32(2):150&#x2013;163. doi: 10.1159/000184748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000184748</ArticleId><ArticleId IdType="pubmed">19088488</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg B., Walgaard C., Drenthen J., Fokke C., Jacobs B.C., van Doorn P.A. Guillain&#x2013;Barr&#xe9; syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469&#x2013;482. doi: 10.1038/nrneurol.2014.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.121</ArticleId><ArticleId IdType="pubmed">25023340</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Triggers of Guillain&#x2013;Barr&#xe9; syndrome: Campylobacter jejuni predominates. Int J Mol Sci. 2022;23(22):14222. doi: 10.3390/ijms232214222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214222</ArticleId><ArticleId IdType="pmc">PMC9696744</ArticleId><ArticleId IdType="pubmed">36430700</ArticleId></ArticleIdList></Reference><Reference><Citation>Meidaninikjeh S., Sabouni N., Taheri M., et al. SARS-CoV-2 and Guillain-Barr&#xe9; syndrome: lessons from viral infections. Viral Immunol. 2022;35(6):404&#x2013;417. doi: 10.1089/vim.2021.0187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2021.0187</ArticleId><ArticleId IdType="pubmed">35766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs B.C., Rothbarth P.H., Van Der Meche F.G.A., et al. The spectrum of antecedent infections in Guillain-Barr&#xe9; syndrome: a case-control study. Neurology. 1998;51(4):1110&#x2013;1115. doi: 10.1212/wnl.51.4.1110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.51.4.1110</ArticleId><ArticleId IdType="pubmed">9781538</ArticleId></ArticleIdList></Reference><Reference><Citation>GeurtsvanKessel C.H., Islam Z., Mohammad Q.D., Jacobs B.C., Endtz H.P., Osterhaus A.D.M.E. Hepatitis E and Guillain-Barr&#xe9; syndrome. Clin Infect Dis. 2013;57(9):1369&#x2013;1370. doi: 10.1093/cid/cit512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit512</ArticleId><ArticleId IdType="pubmed">23899686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz-Weltin M., Frommherz E., Isenmann N., et al. Hepatitis E virus as a trigger for Guillain-Barr&#xe9; syndrome. BMC Neurol. 2021;21(1):304. doi: 10.1186/s12883-021-02334-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02334-1</ArticleId><ArticleId IdType="pmc">PMC8343920</ArticleId><ArticleId IdType="pubmed">34362318</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki N., Hartung H.P. Guillain&#x2013;Barr&#xe9; syndrome. N Engl J Med. 2012;366(24):2294&#x2013;2304. doi: 10.1056/nejmra1114525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmra1114525</ArticleId><ArticleId IdType="pubmed">22694000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.E., Heo J.H., Kim H., et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol. 2017;13(3):227&#x2013;233. doi: 10.3988/jcn.2017.13.3.227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2017.13.3.227</ArticleId><ArticleId IdType="pmc">PMC5532318</ArticleId><ArticleId IdType="pubmed">28748673</ArticleId></ArticleIdList></Reference><Reference><Citation>Aladawi M., Elfil M., Abu-Esheh B., et al. Guillain Barre syndrome as a complication of COVID-19: a systematic review. Can J Neurol Sci. 2022;49(1):38&#x2013;48. doi: 10.1017/cjn.2021.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2021.102</ArticleId><ArticleId IdType="pmc">PMC8267336</ArticleId><ArticleId IdType="pubmed">33949300</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaiodimou L., Stefanou M.I., Katsanos A.H., et al. Prevalence, clinical characteristics and outcomes of Guillain-Barr&#xe9; syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3517&#x2013;3529. doi: 10.1111/ene.14860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14860</ArticleId><ArticleId IdType="pmc">PMC8250909</ArticleId><ArticleId IdType="pubmed">33837630</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosto M., Piccinelli S.C., Gazzina S., et al. Guillain-Barr&#xe9; syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2020;92(7):751&#x2013;756. doi: 10.1136/jnnp-2020-324837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324837</ArticleId><ArticleId IdType="pubmed">33158914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci. 2020;41(11):3149&#x2013;3156. doi: 10.1007/s10072-020-04693-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04693-y</ArticleId><ArticleId IdType="pmc">PMC7464053</ArticleId><ArticleId IdType="pubmed">32876777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel V., Luchsinger V.W., Carvalho G.L., et al. Guillain&#x2013;Barr&#xe9; syndrome associated with COVID-19: a systematic review. Brain Behav Immun Health. 2023;28 doi: 10.1016/j.bbih.2022.100578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100578</ArticleId><ArticleId IdType="pmc">PMC9842533</ArticleId><ArticleId IdType="pubmed">36686624</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyka K.V. Eighty three years of the Guillain-Barr&#xe9; syndrome: clinical and immunopathologic aspects, current and future treatments. Rev Neurol (Paris) 1999;155(10):849&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10546299</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., Sharif K., O'Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6) doi: 10.1016/j.autrev.2020.102537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama T., Hongo Y., Kaida K., Kano O. Guillain-Barr&#xe9; syndrome after COVID-19 in Japan. Case Rep. 2020;13(10):4. doi: 10.1136/bcr-2020-239218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-239218</ArticleId><ArticleId IdType="pmc">PMC7597510</ArticleId><ArticleId IdType="pubmed">33122241</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations. Retreived Aug 20, 2023.</Citation></Reference><Reference><Citation>Zheng C., Shao W., Chen X., et al. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252&#x2013;260. doi: 10.1016/j.ijid.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum H.G., Hadler S.C., Moulia D., et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson &amp; Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021. Morb Mortal Wkly Rep. 2021;70(32):1094&#x2013;1099. doi: 10.15585/mmwr.mm7032e4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7032e4</ArticleId><ArticleId IdType="pmc">PMC8360272</ArticleId><ArticleId IdType="pubmed">34383735</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xu Z., Wang P., et al. New-onset autoimmune phenomena post COVID-19 vaccination. Immunology. 2022;165(4):386&#x2013;401. doi: 10.1111/imm.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M., Singh D., Lown R., et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202&#x2013;2211. doi: 10.1056/nejmoa2105385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2105385</ArticleId><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz N.H., Schultz N.H., S&#xf8;rvoll I.H., et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124&#x2013;2130. doi: 10.1056/nejmoa2104882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson C.R., Shi T., Vasileiou E., et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290&#x2013;1297. doi: 10.1038/s41591-021-01408-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01408-4</ArticleId><ArticleId IdType="pmc">PMC8282499</ArticleId><ArticleId IdType="pubmed">34108714</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara L.J., Vera-Lastra O., Mahroum N., et al. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin Rheumatol. 2022;41(5):1603&#x2013;1609. doi: 10.1007/s10067-022-06149-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06149-4</ArticleId><ArticleId IdType="pmc">PMC8979721</ArticleId><ArticleId IdType="pubmed">35378658</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone F., Cerasuolo P.G., Bosello S.L., et al. Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatol. 2021;3(10):e678&#x2013;e680. doi: 10.1016/S2665-9913(21)00218-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00218-6</ArticleId><ArticleId IdType="pmc">PMC8298028</ArticleId><ArticleId IdType="pubmed">34316728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharabi A., Shiber S., Molad Y. Adult-onset Still's disease following mRNA COVID-19 vaccination. Clin Immunol. 2021;233 doi: 10.1016/j.clim.2021.108878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108878</ArticleId><ArticleId IdType="pmc">PMC8575550</ArticleId><ArticleId IdType="pubmed">34763089</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliulo D., Narayan S., Ue F., Boulougoura A., Badlissi F. Adult-onset Still's disease after mRNA COVID-19 vaccine. Lancet Rheumatol. 2021;3(10):e680&#x2013;e682. doi: 10.1016/S2665-9913(21)00219-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00219-8</ArticleId><ArticleId IdType="pmc">PMC8298008</ArticleId><ArticleId IdType="pubmed">34316726</ArticleId></ArticleIdList></Reference><Reference><Citation>Padiyar S., Kamath N., Mathew J., et al. New-onset Adult-onset Still's disease-like syndrome after ChAdOx1 nCoV-19 vaccination: a case series with review of literature. Clin Rheumatol. 2022;41(5):1569&#x2013;1575. doi: 10.1007/s10067-022-06065-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06065-7</ArticleId><ArticleId IdType="pmc">PMC8764317</ArticleId><ArticleId IdType="pubmed">35041110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon Y.H., Lim D.H., Choi S.W., Choi S.J. A flare of Still's disease following COVID-19 vaccination in a 34-year-old patient. Rheumatol Int. 2022;42(4):743&#x2013;748. doi: 10.1007/s00296-021-05052-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-05052-6</ArticleId><ArticleId IdType="pmc">PMC8602986</ArticleId><ArticleId IdType="pubmed">34797392</ArticleId></ArticleIdList></Reference><Reference><Citation>Roongta R., Mondal S., Haldar S., Kumar M.S., Ghosh A. Two flares of Still's disease after two doses of the ChAdOx1 vaccine. Clin Rheumatol. 2022;41(5):1591&#x2013;1596. doi: 10.1007/s10067-022-06124-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06124-z</ArticleId><ArticleId IdType="pmc">PMC8898172</ArticleId><ArticleId IdType="pubmed">35249157</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho-Dom&#xed;nguez L., Rodr&#xed;guez Y., Polo F., et al. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature. J Transl Autoimmun. 2022;5 doi: 10.1016/j.jtauto.2022.100140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2022.100140</ArticleId><ArticleId IdType="pmc">PMC8730708</ArticleId><ArticleId IdType="pubmed">35013724</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng K., Li X., Yang D., et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. eClinicalMedicine. 2023;63 doi: 10.1016/j.eclinm.2023.102154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102154</ArticleId><ArticleId IdType="pmc">PMC10458663</ArticleId><ArticleId IdType="pubmed">37637754</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinke S., Thakur A., Gartlan C., et al. Inflammasome-mediated immunogenicity of clinical and experimental vaccine adjuvants. Vaccine. 2020;8(3):554. doi: 10.3390/vaccines8030554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030554</ArticleId><ArticleId IdType="pmc">PMC7565252</ArticleId><ArticleId IdType="pubmed">32971761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C., Stella N.C., Mariani G., et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095&#x2013;2097. doi: 10.1007/s10067-020-05180-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05180-7</ArticleId><ArticleId IdType="pmc">PMC7251560</ArticleId><ArticleId IdType="pubmed">32462425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.H., Minn D., Kim Y.K. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci. 2021;14(5):1625&#x2013;1626. doi: 10.1111/cts.13036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13036</ArticleId><ArticleId IdType="pmc">PMC8239866</ArticleId><ArticleId IdType="pubmed">33934534</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelena X., Borrell H., Lopez-Corbeto M., et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564&#x2013;570. doi: 10.1016/j.semarthrit.2020.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7229730</ArticleId><ArticleId IdType="pubmed">32425260</ArticleId></ArticleIdList></Reference><Reference><Citation>Filocamo G., Minoia F., Carbogno S., et al. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol. 2020;48(8):1343&#x2013;1344. doi: 10.3899/jrheum.200483.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200483</ArticleId><ArticleId IdType="pubmed">32335512</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman R.H., Axelrad J.E., Chen A., et al. Covid-19 in immune-mediated inflammatory diseases: case series from New York. N Engl J Med. 2020;383(1):85&#x2013;88. doi: 10.1056/nejmc2009567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc2009567</ArticleId><ArticleId IdType="pmc">PMC7204427</ArticleId><ArticleId IdType="pubmed">32348641</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti S., Balduzzi S., Delvino P., Bellis E., Quadrelli V.S., Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667&#x2013;668. doi: 10.1136/annrheumdis-2020-217424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217424</ArticleId><ArticleId IdType="pmc">PMC7211079</ArticleId><ArticleId IdType="pubmed">32241793</ArticleId></ArticleIdList></Reference><Reference><Citation>Favalli E.G., Agape E., Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. 2020;47(8):1296. doi: 10.3899/jrheum.200507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200507</ArticleId><ArticleId IdType="pubmed">32335513</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>